human hepatitis B immunoglobulin

This medicine is authorised for use in the European Union.


This is a summary of the European public assessment report (EPAR). It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach its recommendations on how to use the medicine.

If you need more information about your medical condition or your treatment, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. If you want more information on the basis for the CHMP recommendations, read the scientific discussion (also part of the EPAR).

This EPAR was last updated on 07/11/2023

Authorisation details

Product details
Agency product number
Active substance
human hepatitis B immunoglobulin
International non-proprietary name (INN) or common name
human hepatitis B immunoglobulin
Therapeutic area (MeSH)
  • Immunization, Passive
  • Hepatitis B
  • Liver Transplantation
Anatomical therapeutic chemical (ATC) code
Publication details
Marketing-authorisation holder
Biotest Pharma GmbH
Date of issue of marketing authorisation valid throughout the European Union
Contact address
Landsteinerstrasse 5
D-63303 Dreieich

Product information

06/11/2023 Zutectra - EMEA/H/C/001089 - N/0062

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Immune sera and immunoglobulins

Therapeutic indication

Prevention of hepatitis B virus (HBV) re-infection in HBsAg and HBV-DNA negative adult patients at least one week after liver transplantation for hepatitis B induced liver failure. HBV-DNA negative status should be confirmed within the last 3 months prior to OLT. Patients should be HBsAg negative before treatment start.

The concomitant use of adequate virostatic agents should be considered as standard of hepatitis B re-infection prophylaxis.

Assessment history

How useful was this page?

Add your rating
2 ratings
1 rating